ProCE Banner Activity

Thinking Through Key Considerations for Emergency Medical Professionals on the Management of Patients With Myeloma Receiving CAR T-Cell Therapy or Bispecific Antibodies

Clinical Thought

Do you know what AEs to look for in patients receiving CAR T-cell and bispecific antibody treatment in multiple myeloma? Read to find out some general management practices for AEs With CAR T-cell and bispecific antibody treatment in MM.

Released: May 22, 2024

Expiration: May 21, 2025

Share

Faculty

Thomas G. Martin

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Hematology
Co-Director, Myeloma Program
University of California,
San Francisco Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty Disclosure

Primary Author

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Hematology
Co-Director, Myeloma Program
University of California,
San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD: consultant/advisor/speaker: GlaxoSmithKline, Pfizer; researcher: Bristol Myers Squibb, Janssen, Sanofi.